Book a demo
Topics · GOVERNANCE-AGENTS

Healthcare Payors Agent Governance Build vs Buy | Moring

The build-vs-buy question for payor agent governance is really a scoping question. Runtime enforcement, identity, policy gates, and audit trails are shared infrastructure every agent needs, which favors buying or adopting a control plane; workflow-specific policy and evaluation belong to the plan. Healthcare payors that build the full stack alone pay for governance repeatedly, once per team.

On this page
  1. Short answer
  2. How it works
  3. FAQs
  4. Related reading
  5. Sources

Short answer

The build-vs-buy question for payor agent governance is really a scoping question. Runtime enforcement, identity, policy gates, and audit trails are shared infrastructure every agent needs, which favors buying or adopting a control plane; workflow-specific policy and evaluation belong to the plan. Healthcare payors that build the full stack alone pay for governance repeatedly, once per team.

How it works

Build versus buy for payor agent governance resolves differently at different layers, and conflating the layers is how programs go wrong. The shared substrate, per-agent identity, credential scoping, runtime policy enforcement, approval gates, audit trails, and cost attribution, is identical whether the agent supports prior authorization or member services. Building that substrate in-house means funding a platform team indefinitely and accepting that every integration the plan builds is another surface it must maintain. Buying it means evaluating vendors on exactly those capabilities rather than on demo appeal.

The workflow-specific layer argues the opposite. The policies that define what a prior authorization agent may read and write, the evaluation criteria for a claims agent's outputs, and the escalation paths for member-facing failures are payor-specific by nature, and no vendor knows the plan's clinical criteria, delegation arrangements, or member communications standards. This layer belongs to the plan regardless of the platform, and a purchase decision should be judged on how cleanly the platform lets the plan express its own policy.

Scale evidence favors the centralized route for the shared layer. Organizations deploying agents across dozens of platforms face duplicated effort, escalating risk, and exploding costs when governance is platform-by-platform, and the enterprise control plane pattern, a governance layer sitting above every platform providing common identity, visibility, and control, exists precisely because per-platform governance does not compound. A payor that builds governance inside one team's stack will rebuild it for the next team, and the audit trail will be two systems that do not agree.

Vendor selection therefore deserves procurement-grade scrutiny. The framework elements that matter, a use case registry, acceptable use policy, oversight tiers, audit standards, and a third-party vendor assessment process, should be evaluated as capabilities, with the contract converting due diligence into enforceable terms covering data use, model changes, incident notice, audit rights, and exit. A governance platform is itself a vendor relationship carrying member data risk, so the same rigor the plan applies to clinical vendors applies here.

Build makes sense in defined circumstances. A plan with an existing identity and policy infrastructure, strong engineering capacity, and a small agent estate may extend what it has rather than adopt an external control plane, provided the result enforces at runtime rather than at deploy time. The failure mode is not building per se; it is building governance that lives inside the agent's own code, because policy enforced from within the agent cannot be trusted to constrain it.

The hybrid answer is the honest one for most payors: buy or adopt the enforcement substrate, build the policy content, and hold both to the same standard. Under the EU AI Act, deployers of high-risk systems carry the record-keeping and oversight obligations regardless of who wrote the software, so the buy decision never transfers accountability. Whichever route a plan chooses, the test is identical: can it block an unauthorized action before it happens, and prove afterward what happened.

Frequently asked questions

Which layers of agent governance should a healthcare payor build itself?

The workflow-specific layer: policies defining what a prior authorization agent may read and write, evaluation criteria for claims outputs, and escalation paths for member-facing failures. These encode the payor's own clinical criteria and delegation arrangements, which no vendor knows. The shared substrate of identity, runtime enforcement, approval gates, and audit trails, by contrast, is identical across workflows and favors adoption over repeated construction.

Why does platform-by-platform governance fail at payor scale?

Because organizations deploying agents across dozens of platforms face duplicated effort, escalating risk, and exploding costs, and their audit trails become disconnected systems that do not agree. The enterprise control plane pattern, common identity, visibility, and control above every platform, exists because per-platform governance does not compound. A healthcare payor that builds governance per team rebuilds it for the next team while oversight fragments.

What contract terms matter when buying a governance platform?

Terms converting due diligence into enforceable commitments: data use restrictions, model change notification, incident notice, audit rights, and exit provisions. A governance platform is itself a vendor relationship carrying member data risk, so the healthcare payor should apply the same procurement rigor it applies to clinical vendors, and verify during pilot that the platform enforces policy at runtime rather than merely documenting it.

Does buying governance transfer accountability under the EU AI Act?

No. Deployers of high-risk systems carry the record-keeping, human oversight, and documentation obligations regardless of who wrote the software, so a purchased control plane changes who implements the controls, not who answers for them. A healthcare payor choosing the buy route should therefore evaluate vendors on the evidence they generate, and retain the workflow policy and oversight decisions inside the plan.

Sources

  1. brookings.edu
  2. arthur.ai
  3. wilcosource.com
  4. bcg.com
  5. merge.dev
  6. atlan.com
  7. sweet.security
  8. dataiku.com
  9. - artificialintelligenceact.eu